All In Biotech

NDA 211855 · Biogen

Vumerity

Diroximel Fumarate · Oral

Last checked: Nov 20, 2026Latest source record: Sep 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 29, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

12

5 Phase 3, 5 recruiting

FAERS reports

12,103

4,667 serious, 368 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 29, 2025.

VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: The mechanism by which diroximel fumarate exerts its therapeutic effect in multiple sclerosis is unknown. MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VUMERITY · DIROXIMEL FUMARATE 231MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Diroximel" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • flushing1,642
  • multiple sclerosis1,122
  • multiple sclerosis relapse998
  • diarrhoea884
  • product dose omission issue829
  • fatigue795
  • nausea760
  • headache635
  • pruritus603
  • memory impairment581
  • fall571
  • abdominal discomfort532

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20163
20174
20186
201925
2020479
20212,041
20222,568
20232,539
20241,855
20251,638
2026944

Recalls

1 FDA enforcement reports for this application.

  • Dec 9, 2020 · Class II · Terminated

    Failed dissolution specifications: out-of-specification test results observed during the buffer stage dissolution testing.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vumerity (Diroximel Fumarate)

2024 spending

$190M

Beneficiaries

2,762

21,014 claims

Per beneficiary

$68,720

$72.31 per unit

View as table
YearSpending
2020$16,976,972
2021$99,890,637
2022$119,582,404
2023$152,400,689
2024$189,805,009

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.